Anagliptin (SK-0403)

Description: Anagliptin (formerly known as SK0403) is a novel, potent, orally bioactive, highly selective inhibitor of DPP-4 (dipeptidyl peptidase 4) with an IC50 of 3.8 nM. It is less selective against DPP-8/9 (IC50 = 68, 60 nM). Anagliptin was approved for the treatment of type 2 diabetes mellitus in Japan in 2012. In addition to glycemic control, these agents showed beneficial effects on lipid metabolism in clinical trials. Anagliptin exhibited a lipid-lowering effect in a hyperlipidemic animal model, and suggested that the downregulation of hepatic lipid synthesis was involved in the effect. Anagliptin might have beneficial effects on lipid metabolism in addition to a glucose-lowering effect.

References: J Diabetes Investig. 2017 Mar; 8(2):155-160; Bioorg Med Chem. 2011 Dec 1; 19(23):7221-7.

Publications Citing Use of InvivoChem Anagliptin: ACS Omega 2021, 6, 11, 7771–7777https://doi.org/10.1021/acsomega.1c00242